Reply to thread

Message

<blockquote data-quote="Mugarolla" data-source="post: 4639994" data-attributes="member: 8481">Let me prove you wrong....AgainI&#039;m actually getting bored proving you wrong. It&#039;s too easy.This clinical progress follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase 1 safety results in an initial cohort of 30 hospitalized and non-hospitalized patients with COVID-19. [URL unfurl=&quot;true&quot;]https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention[/URL]Let me prove you wrong...AgainThe trial with 2000 patients is already underway. We just have not seen any data yet. It does not mean that Regeneron cannot enlist another patient into their trial, say, Trump? Or that Regeneron has not seen any data from this trial.The Phase 3 prevention trial is being conducted at approximately 100 sites and is expected to enroll 2,000 patients in the U.S.; the trial will assess SARS-CoV-2 infection status. The two Phase 2/3 treatment trials in hospitalized (estimated enrollment =1,850) and non-hospitalized (estimated enrollment =1,050) patients are planned to be conducted at approximately 150 sites in the U.S., Brazil, Mexico and Chile, and will evaluate virologic and clinical endpoints, with preliminary data expected later this summer.&nbsp; [URL unfurl=&quot;true&quot;]https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention[/URL]Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron&#039;s investigational double antibody cocktail for the treatment and prevention of COVID-19.&nbsp; Let me help you out. The cocktail is called&nbsp; REGN-COV2.</blockquote>

[QUOTE="Mugarolla, post: 4639994, member: 8481"] Let me prove you wrong....Again I'm actually getting bored proving you wrong. It's too easy. [I]This clinical progress follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase 1 safety results in an initial cohort of [B][SIZE=6]30 hospitalized[/SIZE][/B] and non-hospitalized patients with COVID-19. [/I] [URL unfurl="true"]https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention[/URL] Let me prove you wrong...Again The trial with 2000 patients is already underway. We just have not seen any data yet. It does not mean that Regeneron cannot enlist another patient into their trial, say, Trump? Or that Regeneron has not seen any data from this trial. [I]The Phase 3 prevention trial is being conducted at approximately 100 sites and is expected to enroll [SIZE=6][B]2,000 patients[/B][/SIZE] in the U.S.; the trial will assess SARS-CoV-2 infection status. [B][SIZE=6]The two Phase 2/3 treatment trials in hospitalized [/SIZE][/B](estimated enrollment =1,850) and non-hospitalized (estimated enrollment =1,050) patients are planned to be conducted at approximately 150 sites in the U.S., Brazil, Mexico and Chile, and will evaluate virologic and clinical endpoints, [B][SIZE=6]with preliminary data expected later this summer.[/SIZE][/B] [/I] [URL unfurl="true"]https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention[/URL] [I]Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational [B][SIZE=6]double antibody cocktail[/SIZE][/B] for the treatment and prevention of COVID-19. [/I] Let me help you out. The cocktail is called REGN-COV2. [/QUOTE]

Verification